We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Fujifilm Diosynth Biotechnologies Commissions New Cell Banking Facility
News

Fujifilm Diosynth Biotechnologies Commissions New Cell Banking Facility

Fujifilm Diosynth Biotechnologies Commissions New Cell Banking Facility
News

Fujifilm Diosynth Biotechnologies Commissions New Cell Banking Facility

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Fujifilm Diosynth Biotechnologies Commissions New Cell Banking Facility"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The new CBF is available to the company’s customers either as part of a larger development and manufacturing programme, or as a stand-alone service. It forms the second stage of a major expansion of the company’s mammalian cell culture capabilities at the site, following installation last year of new process development and scale-up capabilities. The asset will support delivery of manufacturing programmes for both Fujifilm Diosynth Biotechnologies’ Billingham UK, and Research Triangle Park, North Carolina, USA facilities.

The next stage of the company’s expansion will be the commissioning of a new cGMP manufacturing facility, also in Billingham, which is well under construction, and due on-line in early Q4 2013. This manufacturing facility, which will primarily utilise single-use technologies, has been designed with input from regulatory authorities and key customers, to offer high flexibility for meeting customers’ needs and setting new standards. It will initially offer 200L and 1000L single-use bioreactors, with 2000L bioreactors already planned for 2014.

Steve Bagshaw, Managing Director, Fujifilm Diosynth Biotechnologies UK, said “I am delighted that we have commissioned the Cell Bank Facility within a year of its commencement, and have already started work on our first customer programme. This is the next step in our strategy to grow our services in the CDMO field, becoming a world-class player across both microbial and mammalian cell culture platforms, offering a full life cycle support for our customers”.

Advertisement